Previous close | 94.11 |
Open | 91.67 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 91.67 - 93.94 |
52-week range | 75.88 - 103.95 |
Volume | |
Avg. volume | 934 |
Market cap | 4.626B |
Beta (5Y monthly) | 0.98 |
PE ratio (TTM) | 0.05 |
EPS (TTM) | 19.03 |
Earnings date | 28 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
CooperVision, a global leader in myopia management, successfully concluded its impactful participation as a Gold sponsor at the 5th World Congress of Paediatric Ophthalmology and Strabismus (WCPOS V) in Kuala Lumpur, Malaysia. Held from July 11 to 13, the event highlighted CooperVision's dedication to advancing paediatric eye health in Asia and underscored its role as a pioneer in myopia control. WCPOS V, hosted by the World Society of Paediatric Ophthalmology and Strabismus, attracted over 1,20
With its stock down 14% over the past three months, it is easy to disregard Cooper Companies (NASDAQ:COO). It is...